Everyone knows the pattern of a crash diet. The weight comes off fast, the results look spectacular, everyone is impressed, and then something snaps, and it all comes back, often with interest. The cruelest part is that the failure never kills the ambition. There is always a next attempt, usually a bigger and more determined one, undertaken with total conviction that this time the plan is different.
Obesity research has lived this exact cycle, not as a metaphor for the patients it hopes to treat but as the literal arc of the field itself. Twice it shed almost everything it had built. Twice it came roaring back. And in 2025, it mounted the most serious attempt of its life, by a wide margin. The question hanging over the whole enterprise is the one that haunts every yo-yo dieter standing on the scale at the start of round three. Is this the time it finally sticks, or just a larger and more expensive version of the same cycle?
The scale of the current attempt is genuinely hard to overstate. Obesity was the second-most studied disease in the entire industry last year, with 184 completed trials, behind only non-small cell lung cancer. That is more than double the field's previous peak, and it happened in a year when almost everything else in drug development was being quietly cut back. Citeline's annual trial report, which came out last month, found that overall trial volumes shrank across the industry and that most therapeutic areas were flat or falling after two straight years of growth. Metabolic disease was the only one that grew at all, up 1.1% on the year. That was enough to lift it into the industry's top three therapeutic areas for the first time since the firm began compiling the data in 2014, pushing central nervous system disorders out of third place in the process. By every measure that the report tracks, the field has never committed to obesity this hard. When everyone else in the room is stepping back from the table and one player is pushing all their chips forward, it is worth understanding why they are so sure.
Why The Scar Tissue Matters
It is the history that should make a careful reader slow down, because the two previous crashes were real, and they hurt real people on the way down. After fen-phen was pulled from the market in 1997, obesity research simply stopped. There were no obesity trials at all in the immediate aftermath of the withdrawal, the field flat on its back and afraid to get up. It rebuilt slowly over the better part of a decade and reached a high of 81 to 82 trials in 2008 and 2009, looking, for a moment, like it had finally found its footing. Then it crashed a second time, falling to 29 trials by 2012 and still stuck at exactly 29 in 2015. The next was Acomplia, withdrawn in Europe and other regions in 2008 over the risk of suicidal ideation and other psychiatric harms.